Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Adebrelimab + EC in First-line Extensive SCLC
NCT06786312Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in small cell lung cancer (SCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival at 1 year. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06786312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786312.